Articles

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Ines Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall pointed out that an epidemiologic analysis of malignant ocular surface tumours found significant differences in geographic prevalence rates in the United States.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting, Dr Denise Freitas reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.

Dr Felipe Medeiros in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.

Dr Roger A. Goldberg, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.

During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Dilsher Dhoot reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular oedema.

Dr Shady Awwad in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and instead contributes to development of more corneal haze.

Intra-arterial tPA treatment could provide benefits for patients with central retinal artery occlusion.

The American Academy of Ophthalmology's annual meeting will proceed November 12 to 15 in New Orleans, Louisiana.

A recently developed tool can help ophthalmologists to assess the quality of findings from real-world studies in retinal diseases. This will help them decide which results are most robust and applicable to their practice.

Ophthalmologists’ close proximity to patients put them at higher risk of contracting the virus.

Evidence shows that higher corneal sensitivity may be associated with pain phenotypes, such as the presence of chronic pain involving the trigeminal system.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

Cataract surgery on very small children presents some unique challenges that can be overcome with the use of a femtosecond laser.

The POAAGG study in African Americans gives insights into the effect of glaucoma on this population and provides data that could lead to gene therapies.

The investigators reported the following most prominent cognitive deficits: processing speed, executive functioning, and phonemic fluency among others.

New serological biomarkers could characterise Sjögren’s syndrome better than traditionally used autoantibodies.

Code-free deep learning models are expected to find applications across a range of areas to improve patient care, increase accessibility to healthcare, accelerate clinical research and enhance medical education.

XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable safety profile.

Susvimo, formerly called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

This three-part feature discusses tips for success when getting started with toric IOLs. Part 1 looks at patient selection and optimising biometry; Part 2 examines IOL calculation; and Part 3 looks at the perioperative period and postoperative troubleshooting.

The Luminopia One VR headset is indicated for improved visual acuity in children ages 4-7 with amblyopia, associated with anisometropia or mild strabismus, after receiving treatment instructions from a trained eye care professional.

Ophthalmologists gather to discuss artificial intelligence and the issue of false negatives, practice for surgeons and Best of the Best at the European Society of Cataract and Refractive Surgeons congress.

Home testing technology is proving to be a key advancement in monitoring and screening glaucoma patients.

Talk of lens selection and patient satisfaction dominated discussion during the Advanced IOLs Symposium; cost vs. benefit analysis emerges as a theme throughout the congress.

New strategies are considered for obtaining information from visual assessments while ensuring compliance from paediatric patients.

Results from Phase 3 trials of bispecific antibody faricimab demonstrate that it is more durable than currently available agents, and it has a good safety profile.